NasdaqGM:RAPPPharmaceuticals
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform?
Rapport Therapeutics, Inc. announced it will present Phase 2a trial results for RAP-219 in focal onset seizures, including 8-week follow-up data, at the American Academy of Neurology Annual Meeting in Chicago on April 18–22, 2026.
The focus on TARPγ8, a protein expressed in specific brain regions linked to seizure origins but with minimal hindbrain presence, highlights a precision approach that may differentiate RAP-219 from broader-acting neuroscience therapies.
We’ll examine how the...